With CAR Ts and islets raising the bar in I&I, what’s the play for Tregs?

As regulatory T cell therapies near a clinical inflection point, key questions include where these cells might fit in the treatment landscape, and whether they can match or best the efficacy of CAR T and islet cell programs, which are setting new expectations for what cell therapies can achieve in autoimmune diseases.

Preliminary data has already suggested that engineered Tregs are safe. This year will bring the first clinical efficacy data from an engineered regulatory T (Treg) cell therapy, offering an early read on whether the suppressive cells can quiet inflammation, and whether the effects are durable enough to justify the costs and complexities of a cell therapy...